Odronextamab

Cat. No. M24811

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Odronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells.

CAS Number	1801338-64-6
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

Related CD20 Products
Obinutuzumab Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20.
Ofatumumab Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation.
Rituximab Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
Glofitamab Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.
Ripertamab Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).

Catalog